Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion. OBJECTIVE: The objective of the study was to determine whether exenatide can restore a more normal pattern of insulin secretion in subjects with DM2. DESIGN: Fasted subjects received iv insulin infusion to reach plasma glucose 4.4-5.6 mmol/liter. Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge. PATIENTS: Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2). Controls included 12 healthy, weight-matched subjects with normal glucose tolerance: nine males, three females; age, 57 +/- 9 yr; and body mass index, 32.0 +/- 3.0 kg/m2. SETTING: The study was conducted at an academic hospital. MAIN OUTCOME MEASURES: Plasma insulin, plasma C-peptide, insulin secretion rate (derived by deconvolution), and plasma glucagon were the main outcome measures. RESULTS: DM2 subjects administered saline had diminished first-phase insulin secretion, compared with healthy control subjects. Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects. In exenatide-treated DM2 subjects, the most common adverse event was moderate nausea (two of 13 subjects). CONCLUSIONS: Short-term exposure to exenatide can restore the insulin secretory pattern in response to acute rises in glucose concentrations in DM2 patients who, in the absence of exenatide, do not display a first phase of insulin secretion. Loss of first-phase insulin secretion in DM2 patients may be restored by treatment with exenatide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [71]
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 2×
“Diabetes duration (yr) 4 2 NA Diabetes treatment [n (%)] -Glucosidase inhibitors 2 (15) NA Metformin 10 (77) NA Diet/exercise 1 (7) NA”
BackgroundSelf-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“Insulin, Cpeptide, and glucagon were determined by specific immunoassays as previously described (28, 29).”
MethodSelf-citation
Cited by
Items 101–200 of 296
The Incretin Mimetic Exenatide as a Monotherapy in Patients with Type 2 Diabetes
Nelson, P., Poon, T., Guan, X., Schnabel, C., Wintle, M., & Fineman, M. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.0024 · Cited by 45
“17 17 Given these interesting (cid:4) -cell effects, further studies evaluating the capacity of incretin mimetics to serve as first choice therapies, and their capacity to sustain glycemic improvements, appear warranted.”
Self-citationDavidson, J. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0469 · Cited by 46
“Controlled clinical trials have demonstrated that exenatide improves first- and second-phase insulin secretion.(89,90) In a 1-year trial of metformin-treated patients, administration of exenatide twice daily or insulin glargine produced similar improvements in HbA 1c levels (P=.”
BackgroundSmits, M. M., Muskiet, M. H. A., Tonneijck, L., Kramer, M. H. H., Diamant, M., van Raalte, D. H., & Serné, E. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305447 · Cited by 44
Kendall, D. M., Kim, D., & Maggs, D. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.385 · Cited by 45
Self-citationProtein nanoparticles as drug delivery systems for cancer theranostics
Hua, Y., Qin, Z., Gao, L., Zhou, M., Xue, Y., Li, Y., & Xie, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.004 · Cited by 45
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Robles, G. I., & Singh‐Franco, D. (2009) · Drug Design Development and Therapy · doi:10.2147/dddt.s3321 · Cited by 46
Long-range negative correlation of glucose dynamics in humans and its breakdown in diabetes mellitus
Ogata, H., Tokuyama, K., Nagasaka, S., Ando, A., Kusaka, I., Sato, N. S., Goto, A., Ishibashi, S., Kiyono, K., Struzik, Z. R., et al. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00241.2006 · Cited by 45
“In vivo, the -cell responds to glucose challenges with characteristic first (within 10 min) and second ( 10 min) phase insulin responses (29), and a prominent feature of Type 2 diabetes is a dramatic reduction in the first-phase insulin secretion (7, 35).”
BackgroundÁlvarez-Castro, P., Sangiao‐Alvarellos, S., Brandón-Sandá, I., & Cordido, F. (2011) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.05.008 · Cited by 55
Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care
Kalra, S., Czupryniak, L., Kilov, G., Lamptey, R., Kumar, A., Unnikrishnan, A., Boudiba, A., Abid, M., Akanov, Z., Latheef, A. A., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0521-2 · Cited by 44
Cabrera, O., FICORILLI, J. V., Shaw, J., Echeverri, F., Schwede, F., Chepurny, O. G., Leech, C. A., & Holz, G. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101484 · Cited by 45
Mining incretin hormone pathways for novel therapies
Wideman, R. D., & Kieffer, T. J. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.02.005 · Cited by 42
A Mathematical Model of the Oral Glucose Tolerance Test Illustrating the Effects of the Incretins
Brubaker, P. L., Ohayon, E. L., D’Alessandro, L. M., & Norwich, K. H. (2007) · Annals of Biomedical Engineering · doi:10.1007/s10439-007-9274-1 · Cited by 45
Formulary Forum: Exenatide: A New Option for the Treatment of Type 2 Diabetes
Yoo, B. K., Triller, D. M., & Yoo, D. J. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h060 · Cited by 39
Pennartz, C., Schenker, N., Menge, B. A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2011) · Diabetes Care · doi:10.2337/dc11-0471 · Cited by 41
Self-citationInterspecies Modeling and Prediction of Human Exenatide Pharmacokinetics
Chen, T., Mager, D. E., & Kagan, L. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0917-z · Cited by 38
“Study A is described in reference (38); Studies B and C are described in reference (39).”
Wei, C. H., Thyagiarajan, M., Hunt, L. P., Cox, R., Bradley, K., Elson, R., Hamilton-Shield, J. P., Stevens, M. C. G., & Crowne, E. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12575 · Cited by 39
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
Unger, J. R., & Parkin, C. G. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0013-5 · Cited by 38
Nauck, M. A., Baranov, O., Ritzel, R. A., & Meier, J. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2953-6 · Cited by 37
Self-citationRecent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 39
“GLP-1RAs increase glucose-induced insulin secretion, improve pancreatic beta cell function, suppress glucagon secretion under hyper- or euglycemic conditions, and reduce gastric emptying with a reduction of significant glycemic rises after a meal [61].”
BackgroundGallwitz, B., KAZDA, C. M., Kraus, P., Nicolay, C., & Schernthaner, G. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0319-4 · Cited by 40
“However, since beta-cell function was also significantly reduced, an add-on therapy such as exenatide that can increase first-phase insulin release and beta-cell function, and may potentially improve beta-cell mass, may be important [43–46].”
BackgroundIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.014 · Cited by 38
Noninsulin glucose-lowering agents for the treatment of patients on dialysis
Flynn, C. A., & Bakris, G. L. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.12 · Cited by 36
Rosenstock, J., Sorli, C. H., Trautmann, M. E., Morales, C., Wendisch, U., Dailey, G., Hompesch, M., Choi, I. Y., Kang, J., Stewart, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2648 · Cited by 34
“Vomiting 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 1 (3) 2 (6)”
InfluentialSelf-citationTriplitt, C. L., McGill, J. B., Porte, D., & Conner, C. S. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-c.1 · Cited by 39
Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A Review
Germino, F. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.020 · Cited by 44
Hompesch, M., Jones‐Leone, A., Carr, M. C., Matthews, J., Zhi, H., Young, M., Morrow, L., & Reinhardt, R. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12398 · Cited by 31
“Results from previous studies have validated this approach for estimation of insulin secretion rates [23,24].”
MethodSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Schneider, E. L., Hearn, B. R., Pfaff, S. J., Reid, R. R., Parkes, D. G., Vrang, N., Ashley, G. W., & Santi, D. V. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00218 · Cited by 32
Mok, T. (2010) · The HKU Scholars Hub (University of Hong Kong) · Cited by 31
Protein-modified nanomaterials: emerging trends in skin wound healing
Sharda, D., Kaur, P., & Choudhury, D. (2023) · Discover Nano · doi:10.1186/s11671-023-03903-8 · Cited by 34
Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass
Jung, K. Y., Kim, K. M., & Lim, S. K. (2014) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2014.38.6.426 · Cited by 34
“Treatment with exenatide also restored first-phase insulin secretion and augmented second-phase insulin secretion when infused intravenously along with glucose in patients with T2DM [41].”
Management of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
“These data suggest that acute improvements in β-cell function occur in patients treated with exenatide [33].”
BackgroundGlucagon-like peptide-1 receptor expression and its functions are regulated by androgen
Zhu, L., Zhou, J., Pan, Y., Lv, J., Liu, Y., Yu, S., & Zhang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109555 · Cited by 27
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 35
“Furthermore, GLP-1/GLP-1R agonists shift the dynamics of insulin secretion towards an earlier response and restore the biphasic profile [39].”
BackgroundMetabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes
Schnabel, C. A., Wintle, M. E., & Kolterman, O. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.1.69 · Cited by 32
“At the cellular level, elevated glucose concentrations cause increased production of reactive oxidant species (ROS) that ultimately contribute to”
BackgroundInfluentialIncretins and their role in the management of diabetes
Frías, J. P., & Edelman, S. V. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32825ea2ba · Cited by 30
Preumont, V., Hermans, M. P., Brichard, S. M., & Buysschaert, M. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.02.001 · Cited by 29
Nikfar, S., Abdollahi, M. R., & Salari, P. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3g883 · Cited by 28
“In vivo and in vitro models of diabetes show that exenatide improves first and second phase of insulin secretion in type 2 diabetic patients [9] and enhances β cell proliferation and pancreatic islet cells regeneration [10,11].”
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Combes, J., Borot, S., Mougel, F., & Penfornis, A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01311.x · Cited by 26
“5 mmol/l) to initial values in less than 3 h with excellent tolerance [106].”
BackgroundPreservation of Beta-Cell Function in Type 2 Diabetes
Nyalakonda, K., Sharma, T., & Ismail‐Beigi, F. (2010) · Endocrine Practice · doi:10.4158/ep10112.ra · Cited by 27
Mazze, R., Strock, E. S., Morgan, B., Wesley, D., Bergenstal, R. M., & Cuddihy, R. M. (2009) · Endocrine Practice · doi:10.4158/ep09046.orr · Cited by 25
Nie, J., Lilley, B. N., Pan, Y. A., Faruque, O. M., Liu, X., Zhang, W., Sanes, J. R., Han, X., & Shi, Y. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00285-13 · Cited by 27
Incretins: a new treatment option for type 2 diabetes?
Geelhoed-Duijvestijn, P. H. L. M. (2007) · PubMed · Cited by 32
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
Triplitt, C., & DeFronzo, R. A. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.3.329 · Cited by 25
Veluthakal, R., Chepurny, O. G., Leech, C. A., Schwede, F., Holz, G. G., & Thurmond, D. C. (2018) · Diabetes · doi:10.2337/db17-1174 · Cited by 26
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
Gastaldelli, A., Brodows, R. G., & D'Alessio, D. (2014) · Clinical Endocrinology · doi:10.1111/cen.12199 · Cited by 24
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
“The GLP-1 receptor agonists, exenatide and liraglutide, both augment first- and second-phase insulin secretion in response to an intravenous (iv) glucose bolus [12,13].”
BackgroundExenatide Use in the Management of Metabolic Syndrome: A Retrospective Database Study
Bhushan, R., Elkind-Hirsch, K. E., Bhushan, M., Butler, W. J., Duncan, K., & Marrioneaux, O. (2008) · Endocrine Practice · doi:10.4158/ep.14.8.993 · Cited by 24
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
Pinelli, N. R., Cha, R., Brown, M. B., & Jaber, L. A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l198 · Cited by 26
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control
Kaihara, K. A., Dickson, L. M., Ellenbroek, J. H., Orr, C. M. D., Layden, B. T., & Wicksteed, B. (2015) · Diabetes · doi:10.2337/db14-1051 · Cited by 22
“Incretins contribute up to 70% of insulin release in response to orally ingested glucose (4), and their administration to individuals with impaired glucose tolerance can restore phasic insulin release (19).”
Gatford, K. L., Sulaiman, S. A., Mohammad, S. N. B., Blasio, M. J. D., Harland, M. L., Simmons, R. A., & Owens, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056553 · Cited by 23
Kumar, A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2350 · Cited by 23
Freeman, J. S. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0467 · Cited by 24
Cirincione, B. B., Edwards, J., & Mager, D. E. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9975-1 · Cited by 23
A once-monthly GLP-1 receptor agonist for treatment of diabetic cats
Schneider, E. L., Reid, R. L., Parkes, D. G., Lutz, T. A., Ashley, G. W., & Santi, D. V. (2019) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2019.07.001 · Cited by 22
Expanded Use of Exenatide in the Management of Type 2 Diabetes
John, L. E., Kane, M. P., Busch, R. S., & Hamilton, R. A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.1.59 · Cited by 20
Impact of incretin on early-phase insulin secretion and glucose excursion
Shen, J., Chen, Z., Chen, C.-F., Zhu, X., & Han, Y. (2013) · Endocrine · doi:10.1007/s12020-012-9867-9 · Cited by 20
“[23] observed lower PG levels and improved first- and secondphase insulin secretions in 13 T2DM patients who underwent continuous subcutaneous infusion of GLP-1.”
BackgroundKetosis-Prone Type 2 Diabetes: A Case Series
Sjöholm, Å. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00684 · Cited by 23
“By inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), sitagliptin increases the level of glucagon-like peptide-1 (GLP-1) and we wanted to harness this to therapeutic advantage, as GLP-1 is both a known trophic and anti-apoptotic factor for β-cells [at least in animal models and in human β-cells ex vivo (17)] and pa…”
BackgroundNielsen, L. L., Okerson, T. E., Holcombe, J. H., & Hoogwerf, B. J. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200214 · Cited by 20
Self-citationRole and development of GLP-1 receptor agonists in the management of diabetes
Egan, J. M., & Chia, C. W. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s4283 · Cited by 21
“54 Thirty weeks of exenatide use also resulted in improved β -cell function based on mathematical modeling of β cell in response to test meal in patients with T2DM who were treated with metformin and/ or sulfonylurea.”
Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics
Zhong, X., Yang, S., Liu, T., Ji, S., Hu, J., & Li, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.050 · Cited by 18
GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo
Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B. J., Tomás, A., Mayor, F., & Murga, C. (2021) · BMC Biology · doi:10.1186/s12915-021-00966-w · Cited by 18
“Activation of the GLP-1R pathway is able to recover both the first and second phase of insulin secretion in human T2D patients [80].”
BackgroundKhan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 19
“In T2D, GLP-1–stimulated insulin secretion is diminished, although this process may be restored with administration of a GLP-1 RA [94].”
BackgroundIncretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Lamounier, R. N., Pareja, J. C., Tambascia, M. A., & Geloneze, B. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9098-y · Cited by 21
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Diamant, M., & van Raalte, D. H. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.011 · Cited by 19
Ancu, O., Mickute, M., Guess, N. D., Hurren, N. M., Burd, N. A., & Mackenzie, R. W. (2020) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2020-0396 · Cited by 23
“Additionally, high-protein diets are linked to increased secretion of incretin peptides, such as glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which play an important role in postprandial insulin response (Fehse et al. 2005).”
BackgroundClinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
Ryan, G. J., Moniri, N. H., & Smiley, D. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120168 · Cited by 19
Watada, H., Shiramoto, M., Irie, S., Terauchi, Y., Yamada, Y., Shiosakai, K., Myobatake, Y., & Taguchi, T. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12849 · Cited by 16
Bortell, R., Yang, C., Loehn, M., Jurczyk, A., Przewozniak, N., Leehy, L., Herrera, P. L., Shultz, L. D., Greiner, D. L., & Harlan, D. M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s87253 · Cited by 17
“In clinical trials with type 2 diabetes (T2D) patients, GLP-1 receptor agonists lowered both fasting and postprandial glucose concentrations; 10,11 GLP-1 receptor agonists also potentiate glucose-dependent insulin secretion, and thus have a low propensity to cause hypoglycemia.”
Prkar1a in the Regulation of Insulin Secretion
Hussain, M. A., Stratakis, C. A., & Kirschner, L. S. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0032-1321866 · Cited by 17
“This ensures that incretin hormones stimulate GSIS only when glucose levels are high, while they are ineffective when insulin levels are below a certain threshold [7, 8].”
BackgroundSarmiento, B. E., Menezes, L. F. S., & Schwartz, E. F. (2019) · Molecules · doi:10.3390/molecules24101846 · Cited by 17
“It significantly increases the two phases of insulin secretion process in patients with T2D, indicating an improvement in the response of pancreatic β cells [289].”
BackgroundUpdate in the Pharmacologic Treatment of Diabetes Mellitus
Odegard, P. S., Setter, S. M., & Iltz, J. L. (2006) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721706294003 · Cited by 16
“A trial evaluating the dose-dependent relationship of subcutaneous exenatide on serum insulin levels noted that serum insulin levels increase dose dependently when fasting glucose levels are still elevated but decrease as plasma glucose levels normalize.(27)”
BackgroundMethodInfluentialXie, P., Peng, Y., & Qiu, L. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119388 · Cited by 17
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Self-citationDesign, synthesis and crystallization of a novel glucagon analog as a therapeutic agent
Li, P., Rogers, T., Smiley, D., DiMarchi, R. D., & Zhang, F. P. Y. (2007) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309107028655 · Cited by 16
“Exendin-4 has been shown to have a much longer half-life and higher agonistic activity towards GLP-1 receptor compared with native GLP-1 (Estall & Drucker, 2006; Fehse et al., 2005).”
BackgroundIncretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer, M. P., Chapman, M. J., Horowitz, M., & Deane, A. M. (2014) · Critical Care · doi:10.1186/cc13737 · Cited by 18
Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes
Molina‐Vega, M., Muñoz‐Garach, A., & Tinahones, F. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420160 · Cited by 16
“the response of pancreatic β cells [33].”
Impact of therapeutic advances on hypoglycaemia in type 2 diabetes
Boyle, P. J., & Zrebiec, J. F. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.795 · Cited by 14
“In addition, these agents reduce glucagon secretion postprandially, promote satiety, decrease food intake, slow gastric emptying [177] and may protect βcell function [178].”
BackgroundMoon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“Intravenous exenatide infusions restored fi rst-phase insulin secretion and augmented the second-phase response in people with type 2 diabetes mellitus 73 .”
BackgroundTreatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 14
“Approved for use in the US in 2005, exenatide can be injected prior to meal intake to improve insulin secretion in individuals with type 2 diabetes [66-74].”
BackgroundEpac2A Makes a New Impact in β-Cell Biology
Holz, G. G., Chepurny, O. G., & Leech, C. A. (2013) · Diabetes · doi:10.2337/db13-0796 · Cited by 13
“The high-fat diet (HFD)-fed mouse model ofobesity-related type 2 diabetes mellitus (T2DM)continues to provide new insights concerning themolecular basis for pancreatic b-cell compensation under conditions of diet-induced insulin resistance.”
BackgroundInfluentialBoston, R., Pei, D., & Moate, P. J. (2009) · Metabolism · doi:10.1016/j.metabol.2009.03.003 · Cited by 15
“The ISEC program has been used in more than 30 published experiments and has facilitated the quantification of C-peptide secretion after the oral glucose tolerance test protocol [18], meal tolerance test [19], graded glucose infusions [20], standard IVGTT [21], tolbutamidemodified IVGTT [22], and 30-minute IVGTT [23].”
MethodSynthesis of protein nanoparticles for drug delivery
Cheng, D., Yong, X., Zhu, T., Qiu, Y., Wang, J., Zhu, H. J., Ma, B., & Xie, J. (2016) · European Journal of BioMedical Research · doi:10.18088/ejbmr.2.2.2016.pp8-11 · Cited by 14
Chan, H. M., Jain, R., Åhrén, B., Pacini, G., & D’Argenio, D. Z. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00687.2010 · Cited by 13
“It is hypothesized that the GLP-1 agonist exenatide stimulates insulin response to exogenous glucose intake through its activation on both firstand second-phase insulin secretion (19).”
BackgroundMcGrath, R. T., HOCKING, S. L., Priglinger, M. L., Day, S., Herkes, G., Krause, M., & Fulcher, G. R. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-008203 · Cited by 14
What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?
Bonde, L., Rosenstock, J., & Triplitt, C. L. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s7-a.1 · Cited by 13
“demonstrated that loss of first-phase insulin secretion in T2DM patients may be restored by treatment with exenatide.(35) Three pivotal clinical trials led to the FDA’s approval of exenatide.”
BackgroundGlucagon‐like peptide‐1 in type 2 diabetes: the β‐cell and beyond
Nauck, M. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00919.x · Cited by 14
Self-citationHashimoto, Y., Tanaka, M., Okada, H., Mistuhashi, K., Kimura, T., Kitagawa, N., Fukuda, T., Majima, S., Fukuda, Y., Tanaka, Y., et al. (2015) · Endocrine · doi:10.1007/s12020-015-0786-4 · Cited by 13
“Indeed, it has been reported that incretin-based therapies, such as GLP-1 receptor agonists [4] and dipeptidyl peptidase 4 (DPP-4) inhibitor [5], represses postprandial hyperglycemia in patients with T2DM.”
BackgroundThe Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions
Gallwitz, B. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.208 · Cited by 14
“org Rev Diabetic Stud (2006) 3:208-216 to restore the first phase of insulin secretion in T2D patients [35].”
BackgroundMolecular Basis of cAMP Signaling in Pancreatic β Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_25 · Cited by 12
“However, first phase GSIS is quickly restored during intravenous infusion of GLP-1 receptor agonist exenatide to these patients (Fehse et al. 2005).”
BackgroundLi, A., Zhang, X., Singla, J., White, K. L., Loconte, V., Hu, C., Zhang, C., Li, S., Li, W., Francis, J. P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265567 · Cited by 11
“The first phase happened within the first 10 min of glucose stimulation, and the second phase lasted from 10 min to four hours [47, 48].”
BackgroundSchwartz, S. S. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802390795 · Cited by 11
Beyond insulin replacement: addressing the additional needs of the diabetes patient
DAILEY, G. E. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00847.x · Cited by 12
Yang, J., Le, Y., Wei, T., Wang, K., Yang, K., Xiao, W., Hong, T., & Wei, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107797 · Cited by 10
Metadata
- Authors
- Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Eli Lilly (United States) (US)
- University of Copenhagen (DK)
- Corresponding author
- Nauck, Michael A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-11
- Volume
- 90
- Issue
- 11
- Pages
- 5991-5997
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2039296612
- Cited by
- 297
- References
- 55
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 24 · 2014: 22 · 2013: 21 · 2012: 9
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, incretin mimetics, glucose-dependent insulin secretion, insulin secretion rate, C-peptide, glucagon, insulin resistance, metformin, acarbose, glucoregulation, GLP-1 receptor
- MeSH terms
- Exenatide, Insulin Secretion, Adult, Diabetes Mellitus, Type 2, Female, Glucose, Humans, Insulin, Male, Middle Aged, Peptides, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.